Figure 1. CLL are sensitive to cerdulatinib especially in cases with poor prognosis.

A. IC₅₀ of cerdulatinib in 60 CLL samples. Isolated CD19⁺ cells from CLL patients were incubated with or without increasing concentrations of cerdulatinib (10¹-10⁵ nM) for 72 hours. Viability was measured by PI staining and was normalized to the matched vehicle control for each specimen (100%). IC₅₀ was then generated using the GraphPad Prism 6 program. B. Dose-response curve for all 60 cases. Each data point represents mean±SE of normalized viability of 60 cases at each of 11 tested concentrations. The overall IC₅₀ was then generated using the GraphPad Prism 6. C. Left panel, Time course of viability reduction. Cells were incubated with DMSO or 2 µM cerdulatinib and cell viability was measured at the indicated time points (N = 12). Data points represent mean±SE. Right panel, Minimal effects of cerdulatinib in normal B cells. Cells were incubated with DMSO or 2 µM cerdulatinib. Viability of CLL cells (N = 12) was compared with B cells (N = 12) at 72 hrs following cerdulatinib addition.